A 33-year-old nulligravid woman presented to her gynecologist after experiencing 5 months of secondary amenorrhea following discontinuation of oral contraceptives. She had undergone normal puberty and menarche with no significant past medical or surgical history. Her family history was unremarkable other than a brother with developmental delay. On exam she was 165 cm tall and weighed 67 kg, with a body mass index of 24.6 kg/m 2 (reference interval, 18.5-24.9 kg/m 2 ). She did not display any evidence of hyperandrogenism (hirsutism or acne), and her pelvic exam was normal. A urine pregnancy test was negative. Initial progestin challenge testing (daily oral administration of 10 mg medroxyprogesterone acetate for 7 days) was negative (no bleeding), indicating that the patient was either hypoestrogenic or that she had a uterine outflow abnormality (e.g., uterine scarring) (1 ). (Progestin challenge testing provides an indirect assessment of serum estradiol concentrations. Due to false positives and negatives associated with progestin challenge testing, as well as the development of assays directly measuring serum estradiol, progestin challenge tests are not routinely used.) A uterine outflow abnormality was deemed to be unlikely given that the patient had normal menses on oral contraceptive pills and she had no history of uterine manipulation or surgery. Her serum prolactin was 8.3 ng/mL (reference interval, 0.2-24.5 ng/mL), her total testosterone (measured by chemiluminescent immunoassay) was 14 ng/dL (reference interval, 14 -76 ng/dL), and her free testosterone (measured by liquid chromatography-tandem mass spectrometry) was 0.2 pg/mL (reference interval, 1.3-9.2 pg/mL). Her serum thyroid-stimulating hormone (TSH) 3 was 3.03 IU/mL (reference interval, 0.36 -4.20 IU/mL) and her follicle-stimulating hormone (FSH) was 57.3 mIU/mL (reference intervals: follicular phase, 2.5-10.2 mIU/mL; midcycle, 3.4 -33.4 mIU/mL; luteal phase, 1.5-9.1 mIU/mL; postmenopausal, 23.0 -116.3 mIU/mL), confirming a diagnosis of hypergonadotropic hypogonadism.
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lion women affected in the US. Ninety percent of POI cases are idiopathic and the remaining 10% of cases are due to ovarian autoimmunity, exposure to chemotherapy, or genetic causes. Fragile X (FX) premutations constitute the most common genetic cause of POI in women with a normal 46,XX karyotype, with up to 3% of sporadic cases of POI attributed to FXPOI. FX disorders are caused by expansions of the CGG repeat region in the 5Ј untranslated region (UTR) of the X-linked fragile X mental retardation 1 (FMR1) gene (5 ), which encodes FX mental retardation protein (FMRP), an RNA binding protein involved in regulation of the translation of specific mRNAs. Expanded CGG repeat regions cause a range of pathologic conditions, and the clinical presentation of these disease states depends on the length and methylation status of the CGG repeats (Fig. 2) .
RESOLUTION OF CASE
This patient was referred to a reproductive endocrinologist for further evaluation and management. Because her FSH concentration was increased in the setting of hypoestrogenism, PCR testing of the FMR1 5Ј UTR identified the patient as having an FMR1 premutation allele with 82 CGG repeats and the second allele containing 51 CGG repeats (reference intervals: normal, 5-44 repeats; intermediate, 45-54; premutation, 55-200; full mutation, Ͼ200 repeats), resulting in a conclusive diagnosis of FXPOI. If the patient's FMR1 results had been within the reference interval, additional testing would have included evaluation of antiadrenal antibodies and antithyroid antibodies, screening for diabetes, and evaluation of karyotypes. Importantly, although FMR1 CGG repeats are implicated in both FX syndrome (FXS) and FXPOI, the mechanisms of disease are very different. In individuals with a full mutation, Ͼ200 CGG repeats are present and an epigenetic shift from histone acetylation to methylation is observed throughout the repeat region. As a consequence, FMR1 gene expression is silenced and the intellectual disability and facial abnormalities characteristic of FXS arise owing to a lack of FMRP in neurons and other cell types (5 ) . Although the patient's brother had not been tested at the time of this report, FXS could certainly explain his history of developmental delay. In individuals with a premutation, 55-200 CGG repeats are present but histones in the repeat region remain acetylated and FMR1 overexpression is observed. The prevailing model indicates that this increased concentration of FMR1 mRNA contributes to POI by sequestering RNA binding proteins and thereby interfering with normal cellular processes, particularly in the ovary. Fortunately, only 12%-28% of women with FMR1 premutations experience POI (6 ) .
The mechanisms responsible for repeat expansion are incompletely understood and represent an area of active investigation. Importantly, repeat expansion and contraction is not observed in somatic cells but is strictly associated with the meiotic process. Repeat expansion from a premutation (55-200 repeats) to a full mutation (Ͼ200 repeats) has been observed only during maternal transmission, indicating the involvement of an oocyte-specific factor in the repeat expansion process. Furthermore, the risk of expansion from a premutation to a full mutation increases with increasing maternal repeat size (5 ). Genetic counseling is recommended for women with a premutation to determine the probability of expansion to a full mutation upon transmission to their children. One factor that modulates the stability of FMR1 CGG repeats is the frequency of AGG interspersions within the CGG repeat track. It has been observed that AGG repeats serve as stabilizing anchors that prevent uncontrolled expansion.
Two predominant disease models have been proposed to explain FXPOI. The first model suggests a prenatal reduction in the developing oocyte pool in premutation carriers, resulting in exhaustion of ovarian capacity at a younger age following normal follicular maturation and ovarian function. The second model describes a normal oocyte pool characterized by increased rates of follicular atresia owing to the toxic effect of FMR1 mRNA accumulation. Studies of mice with Fmr1 premutations support the second model, because mouse premutation carriers exhibit a primordial follicle pool similar to that of wild-type littermates but experience faster follicular loss (7, 8 ) .
DIAGNOSIS OF FXPOI
Conclusive diagnosis of FXPOI requires confirmation of increased serum FSH concentrations and detection of 55-200 CGG repeats in the 5Ј UTR of FMR1. Most clinical laboratories offering FMR1 testing carry out targeted mutation analysis by PCR to investigate the number of CGG repeats. Selected laboratories also assess methylation status or offer complete gene sequencing to identify sequence variants outside the CGG repeat region. Importantly, traditional PCR is highly sensitive when a small number of CGG repeats (Յ120) is present but often fails to amplify full mutations, requiring assessment by methylation-specific Southern blot or multiplex ligation-dependent probe amplification. Newer methods are aimed at overcoming this limitation.
CASE FOLLOW-UP
The patient was referred to a genetic counselor for discussion of her risk for having children with FXS and the patient's family members were encouraged to undergo testing to determine their FMR1 CGG repeat alleles. The patient's reproductive endocrinologist discouraged in vitro fertilization because in vitro fertilization with autologous oocytes is rarely successful in women with a history of amenorrhea and consistently increased FSH concentrations. In exploring alternative options for childbearing, the patient suggested having her younger sister serve as an oocyte donor. Additionally, preimplantation genetic diagnosis of the resulting embryos was proposed to select an embryo with a minimum number of CGG repeats if the patient's sister were to test positive for an FMR1 premutation (9 ) . The patient's sister subsequently underwent clinical evaluation, including FMR1 testing and measurement of serum antimullerian hormone (AMH), an indicator of ovarian reserve (10 ) . The AMH value was 1.8 ng/mL (reference interval for females 13-45 years old, 0.9 -9.5 ng/mL), indicating that a standard gonadotropin stimulation protocol would suffice and the patient's sister could likely serve as an oocyte donor. 
POINTS TO REMEMBER
• Initial evaluation of women with oligomenorrhea/amenorrhea should include measurement of testosterone, TSH, prolactin, and FSH.
• Expansions of the CGG repeat region in the 5Ј UTR of FMR1 cause a range of pathologic conditions, with the clinical presentation dependent on the number of CGG repeats.
• Diagnosis of FXPOI requires detection of an expanded CGG repeat region in the premutation range, by PCR, sequencing, or Southern blot.
• FXPOI constitutes the most common genetic cause of POI, resulting in 3% of sporadic POI cases.
• Serum AMH concentrations reflect ovarian reserve and can be helpful in assessing potential response to gonadotropin stimulation.
